RxDoctor Payments Data

McDavid Mahaffey, MD

Family Medicine · Cleburne, TXNPI 1124163811

Payments from drug & device makers

$9,429in general payments, 2019–2025

Across 596 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$907
  • Novo Nordisk$823
  • Boehringer Ingelheim$664
  • Pfizer$513
  • Corium, LLC$510
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)92$1,247
AstraZeneca49$907
Novo Nordisk77$823
Boehringer Ingelheim32$664
Pfizer39$513
Corium, LLC18$510
GSK21$341
Amgen20$337
Astellas Pharma US Inc17$280
Lilly USA, LLC18$279
Supernus Pharmaceuticals, Inc.16$253
Tris Pharma Inc15$245
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$207
Lundbeck LLC12$193
Amarin Pharma, Inc.10$155
Bayer9$151
Biohaven Pharmaceutical Holding Company Ltd.8$148
Abbott7$138
Ironshore Pharmaceuticals Inc.7$138
Dexcom, Inc.8$132
Takeda Pharmaceuticals U.S.A., Inc.9$131
Vanda Pharmaceuticals Inc.6$124
Otsuka America Pharmaceutical, Inc.7$116
Johnson & Johnson7$105
Merck7$91
Shield Therapeutics Inc4$83
Exact Sciences4$77
E.r. Squibb & Sons, L.L.C.5$77
Nestle Healthcare Nutrition Inc.3$53
Aimmune Therapeutics, Inc.3$50
Sunovion Pharmaceuticals Inc.5$48
Novartis3$47
Ascensia Diabetes Care US Inc.3$46
Phathom Pharmaceuticals, Inc.3$41
Axsome Therapeutics, Inc.2$41
Genentech USA, Inc.3$40
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$37
Lucid Diagnostics Inc.2$35
Radius Health, Inc.1$34
Esperion Therapeutics, Inc.2$30
Biohaven Pharmaceuticals, Inc.2$29
Jazz Pharmaceuticals Inc.2$28
Antares Pharma, Inc.1$25
Kowa Pharmaceuticals America, Inc.2$25
Hikma Pharmaceuticals USA1$24
Halozyme Inc1$23
Xeris Pharmaceuticals, Inc.1$23
IBSA Pharma Inc.1$21
Paratek Pharmaceuticals, Inc.1$20
Ardelyx, Inc.1$20
Seqirus USA Inc1$19
Evofem Biosciences, Inc.1$19
Mycovia Pharmaceuticals, Inc.1$19
Sumitomo Pharma America, Inc.1$19
Duchesnay USA Incorporated1$19
Tactile Systems Technology Inc1$18
Medtronic1$16
Ironwood Pharmaceuticals, Inc1$16
Phadia US Inc.1$14
Noven Therapeutics, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,429 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$356,363
Medicare patients
605
Services billed
21,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin136$176,631
EliquisApixaban166$151,615
OzempicSemaglutide98$136,111
TrulicityDulaglutide90$104,047
JanuviaSitagliptin Phosphate60$77,665
XareltoRivaroxaban57$66,137
RybelsusSemaglutide28$59,059
Bydureon BciseExenatide Microspheres50$58,534
ProliaDenosumab25$43,469
LinzessLinaclotide48$39,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$36,335
FarxigaDapagliflozin Propanediol48$35,166
MounjaroTirzepatide18$19,026
SymbicortBudesonide/Formoterol Fumarate46$18,573
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$18,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$664$205,263169 claims
Novo NordiskOzempic, Rybelsus$823$195,170126 claims
PfizerEliquis$513$151,615166 claims
Lilly USA, LLCTrulicity, Mounjaro$279$123,073108 claims
MerckJanuvia$91$77,66560 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Brilinta$907$74,846123 claims
Johnson & JohnsonXarelto$105$66,13757 claims
AmgenProlia$337$43,46925 claims
GSKTrelegy Ellipta, Breo Ellipta$341$41,77339 claims
AbbVieLinzess$1,247$39,44248 claims
BayerKerendia$151$17,27316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →